

References

I-140

1. Brunelli MJ, Atallah ÁN, da Silva EM. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. *Cochrane Database Syst Rev*. 2016(3):CD009806.
2. Naglazyme [package insert]. Novato. CA: BioMarin; 2005. Revised 3/2013.
3. Giugliani R, Lampe C, Harmatz P, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study. *Am J Med Genet. Part A*. August 2014;164A(8):1953-1964.
4. US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Galsulfase (Naglazyme®) Product approval information, approval letter 125117, 05/2005.
5. Harmatz PR, Garcia P, Guffon N, Randolph LM, Shediak R, et al. Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI. *J Inherit Metab Dis*. 2014;37:277–287.
6. Furujo M, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up. *Mol Genet Metab Rep*. 2017;13: 69–75.
7. Clinical Pharmacology Compendia. 2019 Tampa FL: Gold Standard, Inc. Galsulfase.
8. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
9. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
10. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. Healthcare. 2016.